Letter of intent (required) deadline: Friday, June 19, 2020, 5 p.m*
*LOIs do not need to be submitted to the PI’s Contract and Grants officer in OSR or the Research Process Manager in RMG for approval. All application materials must be submitted through the online application portal:
Eligibility: All Stanford faculty with PI eligibility
The Stanford Alliance for Innovative Medicines (Stanford AIM) is seeking Letters of Intent (LOIs) for target-driven drug discovery proposals from Stanford faculty. Stanford AIM was launched in summer 2017 as a new partnership with Takeda to accelerate the translation of research discoveries at Stanford into next-generation therapies of all modalities. Stanford AIM brings Stanford and Takeda scientists into close collaboration to share ideas, knowhow, and technical acumen. Stanford faculty projects selected to participate in the program will benefit from access to industry drug development know-how and in-kind use of robust industry research functionalities such as medicinal chemistry, high-throughput screening, pharmacokinetics, or safety/toxicity profiling. Stanford will retain all intellectual property from Stanford AIM-supported research and Takeda scientists will get the chance to participate in cutting edge research at one of the nation's top research universities.
The ideal project for Stanford AIM will have a compelling therapeutic rationale, an identified protein target that is amenable to therapeutic intervention, and sufficient evidence to support the rationale for a drug discovery effort. It is essential that the LOI identifies a novel target or a novel approach to a known target with a distinct advantage over existing approaches to that target. Stanford AIM is open to all therapeutic areas and modalities with an emphasis on small molecule or protein therapeutics at this time. The goal of Stanford AIM is to advance selected faculty projects through proof-of-concept in animals by leveraging in-kind access to discovery and preclinical development capabilities through Takeda.
This call is associated with the a partnership between Stanford and Takeda announced here:
Takeda will provide discovery and preclinical development capabilities, resources and expertise. The specific resource commitments for each project will be developed as part of the full proposal development process and ultimately determined by the Stanford AIM Board. It is anticipated that most selected projects will receive in-kind support for ~18 months. Stanford faculty will be responsible for supporting any Stanford PI effort, relevant laboratory personnel effort, as well as any research costs for collaboration activities carried out at Stanford. To help defray collaboration costs incurred at Stanford, Stanford projects selected for entry into AIM can request up to $75,000 in research support from Stanford ChEM-H, as university research, as part of the full proposal budget.
Stanford AIM uses a two-phase process to select projects for support.
Stanford owns all project intellectual property (IP) and data generated through a Stanford AIM projects, whether invented by Stanford or Takeda. For additional information on how general inventions, background IP, knowhow, and licensing are handled in the Stanford AIM program, please contact the program through the email below.
Questions and Contact Info
FAQs can be found at the following location - https://chemh.stanford.edu/programs/stanford-aim/faqs